Polio Eradication Initiative

Polio Eradication Initiative
Name	Polio Eradication Initiative
Founded	1988
Type	Global public health campaign
Headquarters	Geneva, Switzerland
Parent organization	World Health Organization
Partners	World Health Organization; Rotary International; United Nations Children's Fund; Centers for Disease Control and Prevention; Bill & Melinda Gates Foundation

Polio Eradication Initiative

The Polio Eradication Initiative launched in 1988 following a resolution by the World Health Assembly and coordination among World Health Organization, Rotary International, United Nations Children's Fund, Centers for Disease Control and Prevention, and the Bill & Melinda Gates Foundation to eliminate poliomyelitis worldwide; the campaign mobilized resources from institutions associated with Geneva and engaged national authorities in India, Pakistan, Afghanistan, and Nigeria to interrupt wild poliovirus transmission. The Initiative built upon earlier efforts including the Ten Year Plan for vaccine-preventable diseases, drawing on strategies from campaigns such as the Smallpox Eradication Programme and partnerships exemplified by Gavi, the Vaccine Alliance, Médecins Sans Frontières, and bilateral donors like the United States Agency for International Development.

Background

The Initiative originated after the World Health Assembly adopted a resolution to eradicate poliomyelitis, influenced by success stories from the Smallpox Eradication Programme and technical guidance from the Advisory Committee on Poliomyelitis Eradication within the World Health Organization. Early momentum came from advocacy by Rotary International and funding commitments from entities such as the Rockefeller Foundation and the Bill & Melinda Gates Foundation, while surveillance methods evolved from systems used in Expanded Programme on Immunization and outbreaks tracked through laboratories affiliated with the Global Polio Laboratory Network.

Goals and Strategy

Primary goals mirrored the World Health Assembly target to interrupt all wild poliovirus transmission and to certify regions poliovirus-free via regional certification commissions modeled on bodies used during the Smallpox Eradication Programme and overseen by the World Health Organization. Strategic pillars included mass immunization campaigns akin to operations run during Measles Initiative efforts, acute flaccid paralysis surveillance adapted from protocols used by the Global Surveillance Network, and containment of poliovirus in laboratories guided by policies similar to those from the Global Action Plan. Tactics integrated campaign scheduling used in National Immunization Days and microplanning techniques from projects in Bangladesh and India.

Vaccine Types and Delivery

The Initiative used oral polio vaccine (OPV) formulations developed from work by researchers associated with Albert Sabin and inactivated polio vaccine (IPV) based on advances by Jonas Salk; vaccine selection influenced procurement through mechanisms related to Gavi, the Vaccine Alliance and the United Nations Children's Fund. Delivery modes included house-to-house campaigns modeled on strategies from National Immunization Days and fixed-post delivery practiced in programs in Indonesia and Brazil, with cold chain logistics informed by systems from Expanded Programme on Immunization and equipment standards promoted by the World Health Organization.

Global Implementation and Partners

Implementation relied on partnerships among World Health Organization, Rotary International, United Nations Children's Fund, Centers for Disease Control and Prevention, and funders such as the Bill & Melinda Gates Foundation and bilateral agencies like the United States Agency for International Development and UK Department for International Development. Technical support came from networks including the Global Polio Laboratory Network, regional offices of the World Health Organization such as WHO South-East Asia Regional Office and WHO African Regional Office, and operational partners like Médecins Sans Frontières and PATH working with ministries in countries such as India, Nigeria, Pakistan, and Afghanistan.

Progress and Challenges

Progress included certification of regions free of wild poliovirus through regional commissions comparable to those used in the Smallpox Eradication Programme, elimination achievements in Americas, Europe, and South-East Asia driven by campaigns in Cuba, Albania, and India. Challenges persisted in endemic settings where conflict zones like parts of Pakistan and Afghanistan impeded access, vaccine-derived poliovirus events traced by the Global Polio Laboratory Network complicated strategies, and misinformation spread resembling patterns seen in controversies around Vaccine hesitancy and campaigns affected by actors linked to Taliban-controlled areas. Programmatic obstacles included logistics failures similar to those documented in emergency responses to Ebola virus epidemic in West Africa and constraints on surveillance comparable to limitations during outbreaks of Measles.

Regional and Country Experiences

Country experiences varied: India achieved certification after large-scale campaigns coordinated with state governments and partners such as National Polio Surveillance Project, drawing on lessons from mass campaigns in Uttar Pradesh and Bihar; Nigeria navigated complex community engagement in northern states with support from faith leaders and initiatives akin to the Polio Emergency Operations Center; Pakistan integrated strategies across provinces of Balochistan, Khyber Pakhtunkhwa, and Punjab while negotiating access amid security incidents involving groups such as the Tehrik-i-Taliban Pakistan; Afghanistan efforts paralleled humanitarian vaccination campaigns in conflict-affected provinces including Helmand and Kunduz.

Future Prospects and Research

Future prospects hinge on innovations from institutions like Centers for Disease Control and Prevention and research conducted at laboratories linked to the Global Polio Laboratory Network to develop stabilised vaccines, novel OPV candidates, and strategies informed by studies published by researchers affiliated with Johns Hopkins University and London School of Hygiene & Tropical Medicine. Policy decisions will involve stakeholders including the World Health Organization, Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation, and national ministries in planning cessation of OPV, stockpile management, and integration with broader immunization platforms modelled after programmes such as the Integrated Disease Surveillance Programme.

Category:Global health